Get the Stockscreener App
202.50
1.21%
-2.62
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $202.50, with a volume of 1.61M.
It is down -1.21% in the last 24 hours and down -1.18% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$205.12
Open:
$205.17
24h Volume:
1.61M
Relative Volume:
0.23
Market Cap:
$358.14B
Revenue:
$61.16B
Net Income/Loss:
$4.19B
P/E Ratio:
85.75
EPS:
2.3614
Net Cash Flow:
$17.82B
1W Performance:
-2.77%
1M Performance:
-1.18%
6M Performance:
-11.39%
1Y Performance:
+16.61%
1-Day Range:
$202.47
$205.99
1-Week Range:
$200.92
$212.35
52-Week Range:
$174.40
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
202.48 | 362.81B | 61.16B | 4.19B | 17.82B | 2.3614 |
LLY
Lilly Eli Co
|
918.64 | 806.72B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
224.31 | 544.73B | 96.36B | 21.04B | 19.70B | 8.6488 |
AZN
Astrazeneca Plc
|
195.75 | 303.62B | 58.80B | 10.24B | 8.98B | 3.2788 |
NVS
Novartis Ag Adr
|
147.34 | 282.35B | 54.72B | 14.02B | 15.32B | 7.1855 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
ABBV (AbbVie Inc.) posts narrow Q4 2025 EPS beat, shares dip slightly in daily trading.Hot Momentum Watchlist - Cổng thông tin điện tử tỉnh Lào Cai
AbbVie stock moves down with RSI signaling oversold conditions near $204: weekly analysis - Traders Union
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
How a single word could determine the future of 340B - Modern Healthcare
Assessing AbbVie (ABBV) Valuation After Recent Share Price Softness And Lofty P/E Premium - simplywall.st
UChicago Medicine marks one-year countdown to opening of AbbVie Foundation Cancer Pavilion | Newswise - Newswise
ABBV Initiated Coverage by Canaccord Genuity -- Price Target Ann - GuruFocus
Five High-Dividend Stocks With Yields Above 3%: AbbVie, Shell, and Chevron Top the List - CoinCentral
AbbVie initiated with a Buy at Canaccord - TipRanks
Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031Insight on More than 550 Clinical Trials - GlobeNewswire Inc.
Biologics Market: Share and Outlook Driven by Roche, Amgen, and AbbVie Leading Advanced Therapeutics - openPR.com
Here's Why AbbVie (ABBV) Fell More Than Broader Market - Yahoo Finance
AbbVie and BioLabs Team Up to Support Life Sciences Innovation in Canada - Investing News Network
AbbVie Sponsors New BioLabs Facility in Toronto - marketscreener.com
Will AbbVie's Oncology Franchise Weigh on Q1 Top-line Growth? - qz.com
AbbVie And BioLabs Team Up To Support Life Sciences Innovation In Canada - TradingView
AbbVie and BioLabs Team Up to Support Life Sciences Innovation in Canada – Company Announcement - Financial Times
Nxera Pharma Co., Ltd. Reaches Third R&D Milestone Under Collaboration with Abbvie - marketscreener.com
Nxera to receive $10 million milestone from AbbVie deal - The Pharma Letter
AbbVie Makes $10 Million Milestone Payment to Nxera Pharma Under Collaboration - marketscreener.com
The Zacks Analyst Blog Microsoft, AbbVie, BHP, CBL & Associates Properties and IRIDEX - Zacks Investment Research
Top Dividend Stocks for Income: AbbVie & Enbridge Analysis | 2026 MarketNews and Statistics - IndexBox
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases - GlobeNewswire Inc.
AbbVie (ABBV) Is One Of The Major Stock To Buy According To Wall Street - Insider Monkey
Lobbying Update: $180,000 of ABBVIE INC. lobbying was just disclosed - Quiver Quantitative
AbbVie Inc stock (US00287Y1091): Is its immunology dominance strong enough to unlock new upside? - AD HOC NEWS
ABBV Stock Quote Price and Forecast - CNN
Asset Management One Co. Ltd. Has $209.74 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. (ABBV): A Bull Case Theory - MSN
AbbVie Inc. (NYSE:ABBV) Short Interest Update - MarketBeat
PBUThe Pension Fund of Early Childhood & Youth Educators's AbbVie Inc(ABBV) Holding History - GuruFocus
Top Analyst Reports for Microsoft, AbbVie & BHP - Yahoo Finance
Should you buy AbbVie stock before April 29? - MSN
AbbVie inks $745 million deal to develop pain medicines from Chinese drugmaker - Crain's Chicago Business
AbbVie Trades Below 50-Day and 200-Day SMA: How to Play the Stock - The Globe and Mail
AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit - Yahoo Finance
DB&C Advisors, LLC's AbbVie Inc(ABBV) Holding History - GuruFocus
Merit Financial Group LLC Has $21.32 Million Stake in AbbVie Inc. $ABBV - MarketBeat
Pertzye Market Booming with Rapid Growth Through 2033| AbbVie • Nestlé Health Science • Solvay Pharmaceuticals - openPR.com
AE Wealth Management LLC Purchases 7,696 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie, Inc. Trade Ideas — TURQUOISE:4ABD - TradingView
Portfolio Building Block World Pharma and Biotech Index ETF's AbbVie Inc(ABBV) Holding History - GuruFocus
Why AbbVie Is a No-Brainer Stock to Buy on the Dip - AOL.com
AbbVie Steps Deeper Into Obesity Market With New Phase 1 ABBV-295 Trial - TipRanks
AbbVie’s Head-to-Head Psoriasis Study Sets Up New Catalyst for ABBV Investors - TipRanks
ABBV: Abbott Laboratories Reports In-Line EPS and Strong Revenue Beat - GuruFocus
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), McKesson (MCK) and Regeneron (REGN) - The Globe and Mail
Nations Financial Group Inc. IA ADV Has $4.88 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
Lbp Am Sa Purchases 8,678 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie eases the pain with $745m licensing deal - BioXconomy
Cwm LLC Boosts Holdings in AbbVie Inc. $ABBV - MarketBeat
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.10%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):